Merck to build $1B Delaware plant to ensure domestic supply of Keytruda

Update: Adds company confirmation Sundry Photography/iStock Editorial via Getty Images Merck ( NYSE: MRK ) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom. This 470,000 sq. ft.

biologics center will comprise laboratory, manufacturing and warehouse.